Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women.

A single post-lactation dose of cabergoline reduces postpartum mammary cancer incidence by approximately 69% in mice and is linked to lower breast cancer risk in women.

• Why it matters: Postpartum breast cancer often has a poor prognosis, and effective chemoprevention strategies are urgently needed for women at high risk, especially during the postpartum period.
• What they did: Researchers treated Brca1-mutant mice with a single dose of cabergoline, observing delayed cancer onset, reduced ductal area and proliferation, and improved involution; retrospective studies in European women showed an association with decreased breast cancer incidence.
• The result: This work highlights targeting postlactational involution as a promising prevention approach and suggests cabergoline as a low-risk chemopreventive agent for postpartum breast cancer.